DigestRedComo funciona
Red
/
Empresas
Al
No verificado

Aldeyra Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosÓpticaSalud

29 Comunicados de prensa

Ver todos los comunicados de prensa
16/12/2025
Web y redes sociales
Telefonía
Industria
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Óptica
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
13/11/2025
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
Web y redes sociales
Telefonía
Industria
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
11/11/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Web y redes sociales
Finanzas
Eventos
Industria
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
06/11/2025
Finanzas
Web y redes sociales
Oncología
Salud
Ciencia
Farmacéutica
Óptica
Biotecnología
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/10/2025
Multimedia
Industria
Ciencia
Biotecnología
Farmacéutica
Óptica
Salud
Medicina - Varios
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
03/09/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Web y redes sociales
Eventos
Industria
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/08/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Industria
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
19/08/2025
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Óptica
Industria
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
06/08/2025
Biotecnología
Farmacéutica
Óptica
Salud
Eventos
Web y redes sociales
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/07/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
Fuente
Aldeyra Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0